BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BioXcel Therapeutics's ebitda for the twelve months ending Mar 31, 2022 was -$111.73M. For fiscal 2021 it was -$106.64M. The highest annual figure on record is -$4.54M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -$106.64M | – |
| FY2020 | Dec 31, 2020 | -$82.11M | – |
| FY2019 | Dec 31, 2019 | -$33.45M | – |
| FY2018 | Dec 31, 2018 | -$19.95M | – |
| FY2017 | Dec 31, 2017 | -$4.54M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | -$31.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.06M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$27.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$26.31M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.39M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.95M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.48M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.55M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.38M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.11M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.53M | – |
| Q1 FY2017 | Mar 31, 2017 | -$528.00K | – |
See a number that looks wrong?